Fabrazyme er indiceret til langtids- enzymerstatningsterapi hos patienter med en bekræftet diagnosticering af Fabrys sygdom (α- galaktosidase A- mangel).
Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α -galactosidase A deficiency).